(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 135.15% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 88.41%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Crispr Therapeutics Ag's revenue in 2025 is $38,050,000.On average, 11 Wall Street analysts forecast CRSP's revenue for 2025 to be $1,924,692,852, with the lowest CRSP revenue forecast at $289,222,345, and the highest CRSP revenue forecast at $4,802,182,334. On average, 12 Wall Street analysts forecast CRSP's revenue for 2026 to be $19,542,608,340, with the lowest CRSP revenue forecast at $318,326,481, and the highest CRSP revenue forecast at $134,579,340,913.
In 2027, CRSP is forecast to generate $47,637,557,807 in revenue, with the lowest revenue forecast at $4,855,843,084 and the highest revenue forecast at $206,111,848,603.